Multiple sclerosis (MS) is a debilitating disease with few treatment options. But in a new clinical trial, scientists have tested a promising new therapy involving injections of stem cells, which ...

About 400,000 Americans have multiple sclerosis, and up until now, the only drugs offered to them to slow the course of the disease had to be injected or dripped into a vein. But soon, it seems, they ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune response. Copaxone and Glatopa mimic a protein in myelin to ...

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...

– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven ...

Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris VTRS.O and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...